HUAQING ZHIMEI has closed a Series A round for tens of millions of CNY to advance clinical bioprinti...

HUAQING ZHIMEI has closed a Series A round for tens of millions of CNY to advance clinical bioprinting for regenerative medicine. This investment signals a systemic shift toward automated, patient-specific tissue engineering for wound care. By integrating 3D bioprinting with bio-inks, the company is bridging the gap between research and standardized bedside application. This move will accelerate the clinical adoption of bio-printed therapies. 🧬📈 #3DPrinting #Bioprinting #AMIndustry